The role of the host defense system in the development of cerebral vasospasm: Analogies between atherosclerosis and subarachnoid hemorrhage

European Neurology

Volumn 68, Issue 6, 2012, Pages 329-343

  Yanamoto, Hiroji ^a,b   Kataoka, Hiroharu ^a   Nakajo, Yukako ^a,b,c   Iihara, Koji ^a  

^a NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

^b OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c RAKUWAKAI OTOWA HOSPITAL   (Japan)

Author keywords

Atherosclerosis; Cerebral vasospasm; Complement system; Platelet derived growth factor BB; Subarachnoid hemorrhage; Thrombin

Indexed keywords

1 [7 (4 FLUOROPHENYL) 1,2,3,4 TETRAHYDRO 8 (4 PYRIDYL)PYRAZOLO[5,1 C][1,2,4]TRIAZIN 2 YL] 2 PHENYLETHANEDIONE; 4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; ARGATROBAN; CILOSTAZOL; FASUDIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NAFAMSTAT MESILATE; PLATELET DERIVED GROWTH FACTOR AA; PLATELET DERIVED GROWTH FACTOR AB; PLATELET DERIVED GROWTH FACTOR BB; THROMBIN; TRAPIDIL;

ARTERY CONSTRICTION; ARTERY INJURY; ARTERY WALL; BLOOD CLOTTING; BRAIN ATHEROSCLEROSIS; BRAIN ISCHEMIA; BRAIN VASOSPASM; CEREBROSPINAL FLUID; COMPLEMENT SYSTEM; CONTINUOUS INFUSION; DISEASE SEVERITY; DOSE RESPONSE; ENDOTHELIUM CELL; FOREIGN BODY; HISTOLOGY; HOST RESISTANCE; HUMAN; MACROPHAGE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SUBARACHNOID HEMORRHAGE; THROMBOCYTE;

ANIMALS; ATHEROSCLEROSIS; BRAIN ISCHEMIA; HUMANS; PLATELET-DERIVED GROWTH FACTOR; SUBARACHNOID HEMORRHAGE; VASOSPASM, INTRACRANIAL;

EID: 84867681929     PISSN: 00143022     EISSN: 14219913     Source Type: Journal    
DOI: 10.1159/000341336     Document Type: Review

References (137)

1. Claassen J, Bernardini GL, Kreiter K, Bates J, Du YE, Copeland D, Connolly ES, Mayer SA: Effect of cisternal and ventricular blood on risk of delayed cerebral ischemia after sub-arachnoid hemorrhage: the Fisher scale revisited. Stroke 2001; 32:2012-2020.
2. Komotar RJ, Zacharia BE, Valhora R, Mocco J, Connolly ESJ: Advances in vasospasm treatment and prevention. J Neurol Sci 2007; 261: 134-142.
3. Mocco J, Zacharia BE, Komotar RJ, Connolly ESJ: A review of current and future medical therapies for cerebral vasospasm following aneurysmal subarachnoid hemorrhage. Neurosurg Focus 2006; 21:E9.
4. Weir B, Grace M, Hansen J, Rothberg C: Time course of vasospasm in man. J Neuro-surg 1978; 48:173-178.
5. Macdonald RL, Weir BK: A review of hemoglobin and the pathogenesis of cerebral vaso-spasm. Stroke 1991; 22:971-982.
6. Weir B, Macdonald RL, Stoodley M: Etiology of cerebral vasospasm. Acta Neurochir Suppl (Wien) 1999; 72:27-46.
7. Harada T, Suzuki Y, Satoh S, Ikegaki I, Asano T, Shibuya M, Sugita K: Blood component induction of cerebral vasospasm. Neurosur-gery 1990; 27:252-255.
8. Satoh S, Suzuki Y, Harada T, Ikegaki I, Asano T, Shibuya M, Sugita K, Saito A: The role of platelets in the development of cerebral vaso-spasm. Brain Res Bull 1991; 27: 663-668.
9. Peterson JW, Roussos L, Kwun BD, Hackett JD, Owen CJ, Zervas NT: Evidence of the role of hemolysis in experimental cerebral vaso-spasm. J Neurosurg 1990; 72:775-781.
10. Nozaki K, Okamoto S, Yanamoto H, Kikuchi H: Red blood cells are essential for late vaso-spasm following experimentally induced subarachnoid hemorrhage in dogs. Neurol Med Chir (Tokyo) 1990; 30:10-15.
11. Brouwers PJ, Wijdicks EF, Van GJ: Infarction after aneurysm rupture does not depend on distribution or clearance rate of blood. Stroke 1992; 23: 374-379.
12. Aoki T, Takenaka K, Suzuki S, Kassell NF, Sagher O, Lee KS: The role of hemolysate in the facilitation of oxyhemoglobin-induced contraction in rabbit basilar arteries. J Neu-rosurg 1994; 81: 261-266.
13. White RP, Macleod RM, Muhlbauer MS: Evaluation of the role hemoglobin in cere-brospinal fluid plays in producing contractions of cerebral arteries. Surg Neurol 1987; 27: 237-242.
14. Kasuya H, Weir BK, White DM, Stefansson K: Mechanism of oxyhemoglobin-induced release of endothelin-1 from cultured vascular endothelial cells and smooth-muscle cells. J Neurosurg 1993; 79: 892-898.
15. Zimmermann M, Seifert V: Endothelin and subarachnoid hemorrhage: an overview. Neurosurgery 1998; 43:863-876.
16. Pluta RM, Boock RJ, Afshar JK, Clouse K, Bacic M, Ehrenreich H, Oldfield EH: Source and cause of endothelin-1 release into cere-brospinal fluid after subarachnoid hemorrhage. J Neurosurg 1997; 87:287-293.
17. Hino A, Tokuyama Y, Kobayashi M, Yano M, Weir B, Takeda J, Wang X, Bell GI, Macdonald RL: Increased expression of endothelin B receptor mRNA following subarachnoid hemorrhage in monkeys. J Cereb Blood Flow Metab 1996; 16: 688-697.
18. Fassbender K, Hodapp B, Rossol S, Bertsch T, Sch meck J, Schutt S, Fritzinger M, Horn P, Vajkoczy P, Wendel-Wellner M, Ragoschke A, Kuehl S, Brunner J, Schurer L, Schmiedeck P, Hennerici M: Endothelin-1 in sub-arachnoid hemorrhage: an acute-phase reac-tant produced by cerebrospinal fluid leukocytes. Stroke 2000; 31: 2971-2975.
19. Vajkoczy P, Meyer B, Weidauer S, Raabe A, Thome C, Ringel F, Breu V, Schmiedek P: Clazosentan (AXV-034343), a selective en-dothelin A receptor antagonist, in the prevention of cerebral vasospasm following severe aneurysmal subarachnoid hemorrhage: results of a randomized, double-blind, placebo-controlled, multicenter phase IIa study. J Neurosurg 2005; 103: 9-17.
20. Macdonald RL, Higashida RT, Keller E, Mayer SA, Molyneux A, Raabe A, Vajkoczy P, Wanke I, Bach D, Frey A, Marr A, Roux S, Kassell N: Clazosentan, an endothelin receptor antagonist, in patients with aneurysmal subarachnoid haemorrhage undergoing surgical clipping: a randomised, doubleblind, placebo-controlled phase 3 trial (CONSCIOUS-2). Lancet Neurol 2011; 10: 618-625.
21. Sercombe R, Dinh YR, Gomis P: Cerebrovas-cular inflammation following subarachnoid hemorrhage. Jpn J Pharmacol 2002; 88:227-249.
22. Peterson JW, Kwun BD, Teramura A, Hack-ett JD, Morgan JA, Nishizawa S, Bun T, Zer-vas NT: Immunological reaction against the aging human subarachnoid erythrocyte. A model for the onset of cerebral vasospasm after subarachnoid hemorrhage. J Neurosurg 1989; 71: 718-726.
23. Peterson JW, Kwun BD, Hackett JD, Zervas NT: The role of inflammation in experimental cerebral vasospasm. J Neurosurg 1990; 72: 767-774.
24. Yanamoto H, Kikuchi H, Okamoto S, Nozaki K: Cerebral vasospasm caused by cisternal injection of polystyrene latex beads in rabbits is inhibited by a serine protease inhibitor. Surg Neurol 1994; 42: 374-381.
25. Yanamoto H, Kikuchi H, Ishikawa J, Shi-mizu Y, Sato M, Tokuriki Y, Okamoto S, Matsumoto M, Matsumoto K, Nakamura K: Intravenous FUT-175 inhibits complement activation in the cerebrospinal fluid and va-sospasm-related delayed ischemic neurological deficit following subarachnoid hemorrhage; in Findlay JM (ed): Cerebral Vaso-spasm: Proceedings of the Vth International Conference on Cerebral Vasospasm, Edmonton and Jasper, Alberta, Canada, May 17-21, 1993. Amsterdam, Elsevier, 1993, pp 431-434.
26. Ross R, Masuda J, Raines EW, Gown AM, Katsuda S, Sasahara M, Malden LT, Masuko H, Sato H: Localization of PDGF-B protein in macrophages in all phases of atherogene-sis. Science 1990; 248: 1009-1012.
27. Seifert PS, Hugo F, Tranum-Jensen J, Zah-ringer U, Muhly M, Bhakdi S: Isolation and characterization of a complement-activating lipid extracted from human atherosclerotic lesions. J Exp Med 1990; 172:547-557.
28. Oksjoki R, Kovanen PT, Pentikäinen MO: Role of complement activation in atherosclerosis. Curr Opin Lipidol 2003; 14:477-482.
29. Andrae J, Gallini R, Betsholtz C: Role of platelet-derived growth factors in physiology and medicine. Genes Dev 2008; 22: 1276-1312.
30. Torzewski M, Klouche M, Hock J, Messner M, Dorweiler B, Torzewski J, Gabbert HE, Bhakdi S: Immunohistochemical demonstration of enzymatically modified human LDL and its colocalization with the terminal complement complex in the early atherosclerotic lesion. Arterioscler Thromb Vasc Biol 1998; 18: 369-378.
31. Ross R, Vogel A: The platelet-derived growth factor. Cell 1978; 14:203-210.
32. Wagsater D, Zhu C, Bjorck HM, Eriksson P: Effects of PDGF-C and PDGF-D on monocyte migration and MMP-2 and MMP-9 expression. Atherosclerosis 2009; 202:415-423.
33. Raines EW, Bowen-Pope DF, Ross R: Platelet-derived growth factor; in Sporn MB, Roberts AB (eds): Handbook of Experimental Pharmacology: Peptide Growth Factors and Their Receptors. Berlin, Springer, 1990, vol 95/I, pp 173-262.
34. Iihara K, Sasahara M, Hashimoto N, Uemu-ra Y, Kikuchi H, Hazama F: Ischemia induces the expression of platelet-derived growth factor-B chain in neurons and brain macrophages in vivo. J Cereb Blood Flow Metab 1994; 14:818-824.
35. Smits A, Hermansson M, Nistér M, Kar-nushina I, Heldin CH, Westermark B, Funa K: Rat brain capillary endothelial cells express functional PDGF B-type receptors. Growth Factors 1989; 2:1-8.
36. Smits A, Ballagi AE, Funa K: PDGF-BB exerts trophic activity on cultured GABA interneurons from the newborn rat cerebellum. Eur J Neurosci 1993; 5:986-994.
37. Smits A, Kato M, Westermark B, Nistér M, Heldin CH, Funa K: Neurotrophic activity of platelet-derived growth factor (PDGF): rat neuronal cells possess functional PDGF ß-type receptors and respond to PDGF. Proc Natl Acad Sci USA 1991; 88:8159-8163.
38. Savikko J, von Willebrand E: Coexpression of platelet-derived growth factors AA and BB and their receptors during monocytic differentiation. Transplant Proc 2001; 33: 2307-2308.
39. Iihara K, Sasahara M, Hashimoto N, Hazama F: Induction of platelet-derived growth factor ß-receptor in focal ischemia of rat brain. J Cereb Blood Flow Metab 1996; 16: 941-949.
40. Sakata M, Yanamoto H, Hashimoto N, Iihara K, Tsukahara T, Taniguchi T, Kikuchi H: Induction of infarct tolerance by platelet-derived growth factor against temporary focal ischemia. Brain Res 1998; 784:250-255.
41. Iihara K, Hashimoto N, Tsukahara T, Sakata M, Yanamoto H, Taniguchi T: Platelet-derived growth factor-BB, but not-AA, prevents delayed neuronal death after forebrain ischemia in rats. J Cereb Blood Flow Metab 1997; 17:1097-1106.
42. Kamiyama M, Utsunomiya K, Taniguchi K, Yokota T, Kurata H, Tajima N, Kondo K: Contribution of Rho A and Rho kinase to platelet-derived growth factor-BB-induced proliferation of vascular smooth muscle cells. J Atheroscler Thromb 2003; 10:117-123.
43. Sawada N, Itoh H, Ueyama K, Yamashita J, Doi K, Chun TH, Inoue M, Masatsugu K, Saito T, Fukunaga Y, Sakaguchi S, Arai H, Ohno N, Komeda M, Nakao K: Inhibition of rho-associated kinase results in suppression of neointimal formation of balloon-injured arteries. Circulation 2000; 101:2030-2033.
44. Shibata R, Kai H, Seki Y, Kato S, Morimatsu M, Kaibuchi K, Imaizumi T: Role of Rho-as-sociated kinase in neointima formation after vascular injury. Circulation 2001; 103:284-289.
45. Rubin K, Tingström A, Hansson GK, Lars-son E, Rönnstrand L, Klareskog L, Claesson-Welsh L, Heldin CH, Fellström B, Terracio L: Induction of B-type receptors for platelet-derived growth factor in vascular inflammation: possible implications for development of vascular proliferative lesions. Lancet 1988; 1: 1353-1356.
46. Wilcox JN, Smith KM, Williams LT, Schwartz SM, Gordon D: Platelet-derived growth factor mRNA detection in human atherosclerotic plaques by in situ hybridization. J Clin Invest 1988; 82: 1134-1143.
47. Huwiler A, Fabbro D, Pfeilschifter J: Platelet-derived growth factor stimulates de-novo synthesis of mitogen-activated protein ki-nase in renal mesangial cells. Eur J Biochem 1995; 227:209-213.
48. Benzaquen LR, Nicholson-Weller A, Hal-perin JA: Terminal complement proteins C5b-9 release basic fibroblast growth factor and platelet-derived growth factor from en-dothelial cells. J Exp Med 1994; 179:985-992.
49. Lappegård KT, Bergseth G, Riesenfeld J, Pharo A, Magotti P, Lambris JD, Mollnes TE: The artificial surface-induced whole blood inflammatory reaction revealed by increases in a series of chemokines and growth factors is largely complement dependent. J Biomed Mater Res A 2008; 87:129-135.
50. Buono C, Come CE, Witztum JL, Maguire GF, Connelly PW, Carroll M, Lichtman AH: Influence of C3 deficiency on atherosclerosis. Circulation 2002; 105: 3025-3031.
51. Yasojima K, Schwab C, McGeer EG, McGeer PL: Generation of C-reactive protein and complement components in atherosclerotic plaques. Am J Pathol 2001; 158:1039-1051.
52. Nagata I, Zhang Z, Sawada M, Hashimoto N, Kikuchi H, Yanamoto H: Systemically administered thrombin inhibitors can prevent neo-intimal formation and cerebral vasospasm: the possible role of thrombin and PDGF-BB in vascular pathogeneses; in Kikuchi H (ed): Strategic Medical Science Against Brain Attack. Tokyo, Springer, 2002, pp 234-253.
53. Badgett A, Bonner JC, Brody AR: Interferon-gamma modulates lung macrophage production of PDGF-BB and fibroblast growth. J Lipid Mediat Cell Signal 1996; 13: 89-97.
54. Bohm M, Blasius S, Roessner A: Immunohis-tochemical localization of PDGF B, PDGF beta receptors and IGF I receptors during atherogenesis. Zentralbl Pathol 1994; 140: 357-362.
55. Ikari N, Sakai Y, Hitomi Y, Fujii S: New synthetic inhibitor to the alternative complement pathway. Immunology 1983; 49:685-691.
56. Fujii S, Hitomi Y: New synthetic inhibitors of C1r, C1 esterase, thrombin, plasmin, kalli-krein and trypsin. Biochim Biophys Acta 1981; 661: 342-345.
57. Hitomi Y, Fujii S: Inhibition of various im-munological reactions in vivo by a new synthetic complement inhibitor. Int Arch Allergy Appl Immunol 1982; 69: 262-267.
58. Sawada M, Yanamoto H, Nagata I, Hashimoto N, Nakahara I, Akiyama Y, Kikuchi H: Prevention of neointimal formation by a serine protease inhibitor, FUT-175, after carotid balloon injury in rats. Stroke 1999; 30:644-650.
59. Ko SB, Choi HA, Carpenter AM, Helbok R, Schmidt JM, Badjatia N, Claassen J, Connolly ES, Mayer SA, Lee K: Quantitative analysis of hemorrhage volume for predicting delayed cerebral ischemia after subarachnoid hemorrhage. Stroke 2011; 42: 669-674.
60. Rinkel GJ, Wijdicks EF, Vermeulen M, Hasan D, Brouwers PJ, Van GJ: The clinical course of perimesencephalic nonaneurys-mal subarachnoid hemorrhage. Ann Neurol 1991; 29: 463-468.
61. Kasuya H, Shimizu T: Activated complement components C3a and C4a in cerebrospinal fluid and plasma following subarachnoid hemorrhage. J Neurosurg 1989; 71: 741-746.
62. Mack WJ, Ducruet AF, Hickman ZL, Garrett MC, Albert EJ, Kellner CP, Mocco J, Connolly ESJ: Early plasma complement C3a levels correlate with functional outcome after aneurysmal subarachnoid hemorrhage. Neurosurgery 2007; 61: 255-260.
63. Nagata K, Sasaki T, Mori T, Nikaido H, Kobayashi E, Kim P, Kirino T: Cisternal talc injection in dog can induce delayed and prolonged arterial constriction resembling cerebral vasospasm morphologically and pharmacologically. Surg Neurol 1996; 45: 442-447.
64. Mori T, Nagata K, Ishida T, Nikaido H, Ko-bayashi E, Sasaki T, Ohami H, Kirino T: Sequential morphological changes of the con-strictive basilar artery in a canine model of experimental cerebral vasospasm by talc injection. J Vet Med Sci 1994; 56: 535-540.
65. Recinos PF, Pradilla G, Thai QA, Perez M, Hdeib AM, Tamargo RJ: Controlled release of lipopolysaccharide in the subarachnoid space of rabbits induces chronic vasospasm in the absence of blood. Surg Neurol 2006; 66: 463-469.
66. German JW, Gross CE, Giclas P, Watral W, Bednar MM: Systemic complement depletion inhibits experimental cerebral vaso-spasm. Neurosurgery 1996; 39:141-145.
67. Clatterbuck RE, Gailloud P, Ogata L, Gebre-mariam A, Dietsch GN, Murphy KJ, Tama-rgo RJ: Prevention of cerebral vasospasm by a humanized anti-CD11/CD18 monoclonal antibody administered after experimental subarachnoid hemorrhage in nonhuman primates. J Neurosurg 2003; 99: 376-382.
68. Yanamoto H, Kikuchi H, Okamoto S: Effects of protease inhibitor and immunosuppres-sant on cerebral vasospasm after subarach-noid hemorrhage in rabbits. Surg Neurol 1994; 42:382-387.
69. Nagata K, Sasaki T, Mori T, Ooami H, Nirei H, Hamada K, Kirino T: Both cyclosp or ine A and FK-506 failed to prevent cerebral vaso-spasm in canine two hemorrhage model; in Findlay JM (ed): Cerebral Vasospasm: Proceedings of the Vth International Conference on Cerebral Vasospasm, Edmonton and Jasper, Alberta, Canada, May 17-21, 1993. Amsterdam, Elsevier, 1993, pp 439-442.
70. Gaetani P, Tancioni F, Grignani G, Tartara F, Merlo EM, Brocchieri A, Rodriguezy Baena R: Platelet derived growth factor and sub-arachnoid haemorrhage: a study on cisternal cerebrospinal fluid. Acta Neurochir (Wien) 1997; 139: 319-324.
71. Maeda Y, Hirano K, Hirano M, Kikkawa Y, Kameda K, Sasaki T, Kanaide H: Enhanced contractile response of the basilar artery to platelet-derived growth factor in subarach-noid hemorrhage. Stroke 2009; 40: 591-596.
72. Zhang Z, Nagata I, Kikuchi H, Xue JH, Sakai N, Sakai H, Yanamoto H: Broad-spectrum and selective serine protease inhibitors prevent expression of platelet-derived growth factor-BB and cerebral vasospasm after subarachnoid hemorrhage: vasospasm caused by cisternal injection of recombinant platelet-derived growth factor-BB. Stroke 2001; 32:1665-1672.
73. Sachinidis A, Locher R, Hoppe J, Vetter W: The platelet-derived growth factor isomers, PDGF-AA, PDGF-AB and PDGF-BB, induce contraction of vascular smooth muscle cells by different intracellular mechanisms. FEBS Lett 1990; 275:95-98.
74. Berk BC, Alexander RW, Brock TA, Gimbro-ne MA Jr, Webb RC: Vasoconstriction: a new activity for platelet-derived growth factor. Science 1986; 232:87-90.
75. Bassett JE, Bowen-Pope DF, Takayasu M, Dacey RG Jr: Platelet-derived growth factor does not constrict rat intracerebral arterioles in vitro. Microvasc Res 1988; 35: 368-373.
76. Miller CA, Lombard FW, Wu CT, Hubbard CJ, Silbajoris L, Borel CO, Niklason LE: Role of vascular mitogens in subarachnoid hemorrhage-associated cerebral vasculopathy. Neurocrit Care 2006; 5:215-221.
77. Zhang ZW, Yanamoto H, Nagata I, Miyamoto S, Nakajo Y, Xue JH, Iihara K, Kikuchi H: Platelet-derived growth factor-induced severe and chronic vasoconstriction of cerebral arteries: proposed growth factor explanation of cerebral vasospasm. Neurosurgery 2010; 66: 728-735.
78. Claesson-Welsh L: Platelet-derived growth factor receptor signals. J Biol Chem 1994; 269: 32023-32026.
79. Yanamoto H, Kikuchi H, Okamoto S, Noza-ki K: Preventive effect of synthetic serine protease inhibitor, FUT-175, on cerebral va-sospasm in rabbits. Neurosurgery 1992; 30: 351-357.
80. Yanamoto H, Kikuchi H, Sato M, Shimizu Y, Yoneda S, Okamoto S: Therapeutic trial of cerebral vasospasm with the serine protease inhibitor, FUT-175, administered in the acute stage after subarachnoid hemorrhage. Neurosurgery 1992; 30: 358-363.
81. Kaminogo M, Yonekura M, Onizuka M, Ya-sunaga A, Shibata S: Combination of serine protease inhibitor FUT-175 and thrombox-ane synthetase inhibitor OKY-046 decreases cerebral vasospasm in patients with sub-arachnoid hemorrhage. Neurol Med Chir (Tokyo) 1998; 38:704-709.
82. Shuman MA: Thrombin-cellular Interactions. Ann NY Acad Sci 1986; 485:228-239.
83. Narayanan S: Multifunctional roles of thrombin. Ann Clin Lab Sci 1999; 29:275-280.
84. Chen LB, Buchanan JM: Mitogenic activity of blood components. 1. Thrombin and pro-thrombin. Proc Natl Acad Sci USA 1975; 72: 131-135.
85. Tsur utani H, Ohkuma H, Suzuki S: Effects of thrombin inhibitor on thrombin-related signal transduction and cerebral vasospasm in the rabbit subarachnoid hemorrhage model. Stroke 2003; 34: 1497-1500.
86. Suzuki M, Otawara Y, Kuto A, Yoshida K, Kubo Y, Doi M, Ogasawara K, Suzuki T, Ku-roda K, Ogawa A: Prophylactic effect of ar-gatroban for vasospasm following subarach-noid hemorrhage. Proceedings of the 14th Spasm Symposium, Kyoto, 1988, pp 350-353.
87. Kasuya H, Shimizu T, Takakura K: Thrombin activity in CSF after SAH is correlated with the degree of SAH the persistence of subarachnoid clot and the development of vasospasm. Acta Neurochir (Wien) 1998; 140: 579-584.
88. Jerius H, Beall A, Woodrum D, Epstein A, Brophy C: Thrombin-induced vasospasm: cellular signaling mechanisms. Surgery 1998; 123:46-50.
89. Nelken NA, Soifer SJ, O'keefe J, Vu TKH, Charo IF, Coughlin SR: Thrombin receptor expression in normal and atherosclerotic human arteries. J Clin Invest 1992; 90:1614-1621.
90. Maeda Y, Hirano K, Kai Y, Hirano M, Suzuki SO, Sasaki T, Kanaide H: Up-regulation of proteinase-activated receptor 1 and increased contractile responses to thrombin after subarachnoid haemorrhage. Br J Pharmacol 2007; 152:1131-1139.
91. Hirashima Y, Nakamura S, Suzuki M, Kuri-moto M, Endo S, Ogawa A, Kakaku A: Cere-brospinal fluid tissue factor and thrombin-antithrombin III complex as indicators of tissue injury after subarachnoid hemorrhage. Stroke 1997; 28:1666-1670.
92. Kameda K, Kikkawa Y, Hirano M, Matsuo S, Sasaki T, Hirano K: Combined argatro-ban and anti-oxidative agents prevents increased vascular contractility to thrombin and other ligands after subarachnoid hemorrhage. Br J Pharmacol 2012; 165:106-119.
93. Liao JK, Seto M, Noma K: Rho kinase (ROCK) inhibitors. J Cardiovasc Pharmacol 2007; 50:17-24.
94. Shimokawa H, Rashid M: Development of Rho-kinase inhibitors for cardiovascular medicine. Trends Pharmacol Sci 2007; 28: 296-302.
95. Shimokawa H, Seto M, Katsumata N, Ama-no M, Kozai T, Yamawaki T, Kuwata K, Kandabashi T, Egashira K, Ikegaki I, Asano T, Kaibuchi K, Takeshita A: Rho-kinase-mediated pathway induces enhanced myo-sin light chain phosphorylations in a swine model of coronary artery spasm. Cardio-vasc Res 1999; 43:1029-1039.
96. Miyagi Y, Carpenter RC, Meguro T, Parent AD, Zhang JH: Upregulation of rho A and rho kinase messenger RNAs in the basilar artery of a rat model of subarachnoid hemorrhage. J Neurosurg 2000; 93: 471-476.
97. Sato M, Tani E, Fujikawa H, Kaibuchi K: Involvement of Rho-kinase-mediated phos-phorylation of myosin light chain in enhancement of cerebral vasospasm. Circ Res 2000; 87: 195-200.
98. Sasaki T, Kasuya H, Onda H, Sasahara A, Goto S, Hori T, Inoue I: Role of p38 mito-gen-activated protein kinase on cerebral vasospasm after subarachnoid hemorrhage. Stroke 2004; 35: 1466-1470.
99. Watts EJ, Rose MT: Platelet-derived growth factor acts via both the Rho-kinase and p38 signaling enzymes to stimulate contraction in an in vitro model of equine wound healing. Domest Anim Endocrinol 2010; 38: 253-259.
100. Iwasa K, Bernanke DH, Smith RR, Yama-moto Y: Nonmuscle arterial constriction after subarachnoid hemorrhage: role of growth factors derived from platelets. Neu-rosurgery 1993;32:619-624.
101. Onoda K, Ono S, Ogihara K, Shiota T, Asari S, Ohmoto T, Ninomiya Y: Role of extracel lu lar matrix in experi mental vasospasm. Inhibitory effect of antisense oligonucle-otide on collagen induction. Stroke 1996; 27:2102-2108.
102. Suzuki Y, Yamaguchi K, Shimada S, Kita-mura Y, Ohnishi H: Antithrombotic activity and the mecahnism of action of trapidil (Rocornal). Prostaglandins Leukot Med 1982;9:685-695.
103. Hirayama A, Kodama K, Yui Y, Nonogi H, Sumiyoshi T, Origasa H, Hosoda S, Kawaim C: Effect of trapidil on cardiovascular events in patients with coronary artery disease (results from the Japan Multicenter Investigation for Cardiovascular Diseases-Mochida [JMIC-M]). Am J Cardiol 2003; 92:789-793.
104. Hoshiya M, Awazu M: Trapidil inhibits platelet-derived growth factor-stimulated mitogen-activated protein kinase cascade. Hypertension 1998;31:665-671.
105. Gesualdo L, Di Paolo S, Ranieri E, Schena FP: Trapidil inhibits human mesangial cell proliferation: effect on PDGF b-receptor binding and expression. Kidney Int 1994; 46:1002-1009.
106. Ishikura K, Fujita H, Hida M, Awazu M: Trapidil inhibits platelet-derived growth factor-induced migration via protein ki-nase A and RhoA/Rho-associated kinase in rat vascular smooth muscle cells. Eur J Pharmacol 2005;515:28-33.
107. Suzuki S, Sobata E, Iwabuchi T: Prevention of cerebral ischemic symptoms in cerebral vasospasm with trapidil, an antagonist and selective synthesis inhibitor of thrombox-ane A2. Neurosurgery 1981;9:679-685.
108. Iwabuchi S, Yokouchi T, Hayashi M, Uehara H, Ueda M, Samejima H: Intra-arterial administration of fasudil hydrochloride for vasospasm following subarachnoid hemorrhage-analysis of time-density curve with digital subtraction angiography. Neurol Med Chir (Tokyo) 2006;46:535-539.
109. Sibuya M, Suzuki Y, Sugita K, Saito I, Sasaki T, Takakura K, Nagata I, Kikuchi H, Takemae T, Hidaka H, Nakashima M: Effect of AT877 on cerebral vasospasm after aneurysmal subarachnoid hemorrhage. Results of a prospective placebo-controlled double-blind trial. J Neurosurg 1992;76: 571-577.
110. Suzuki Y, Shibuya M, Satoh S, Sugimoto Y, Takakura K: A postmarketing surveillance study of fasudil treatment after aneurysmal subarachnoid hemorrhage. Surg Neurol 2007;68:126-131.
111. Nagumo H, Sasaki Y, Ono Y, Okamoto H, Seto M, Takuwa Y: Rho kinase inhibitor HA-1077 prevents Rho-mediated myosin phosphatase inhibition in smooth muscle cells. Am J Physiol Cell Physiol 2000; 278:C57-C65.
112. Suzuki Y, Shibuya M, Satoh S, Sugiyama H, Seto M, Takakura K: Safety and efficacy of fasudil monotherapy and fasudil-ozagrel combination therapy in patients with sub-arachnoid hemorrhage: sub-analysis of the post-marketing surveillance study. Neurol Med Chir (Tokyo) 2008;48:241-247.
113. Ono K, Shirotani T, Wada K, Takahara T, Matsushita Y, Yuba K, Yamana D: Intra-ar-terial administration of fasudil hydrochlo-ride: duration of action (in Japanese). No Shinkei Geka 2005;33:133-140.
114. Anei R, Iihara K, Yanamoto H, Zhang Z, Higashi T, Murao K, Kogure S, Takahashi J, Hayashi K, Nagamine T, Ishibashi T, Soeda A, Taniguchi A, Fukuda H, Fukui N, Na-gata I: Treatment for cerebral vasospasm with nonselective serine protease inhibitor, FUT-175 and selective serine protease inhibitor for thrombin, argatroban. Sur-gery Cerebral Stroke (Japanese) 2002;30 (suppl):88-91.
115. Shaw SM, Fildes JE, Yonan N, Williams SG: Pleiotropic effects and cholesterol-lowering therapy. Cardiology 2008;112:4-12.
116. Zhou Q, Liao JK: Rho kinase: an important mediator of atherosclerosis and vascular disease. Curr Pharm Des 2009;15:3108-3115.
117. Ikeda T, Nakamura K, Akagi S, Kusano KF, Matsubara H, Fujio H, Ogawa A, Miura A, Miura D, Oto T, Yamanaka R, Otsuka F, Date H, Ohe T, Ito H: Inhibitory effects of simvastatin on platelet-derived growth factor signaling in pulmonary artery smooth muscle cells from patients with idiopathic pulmonary arterial hypertension. J Cardio-vasc Pharmacol 2010;55:39-48.
118. Kuzuya M, Cheng XW, Sasaki T, Tamaya-Mori N, Iguchi A: Pitavastatin, a 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor, blocks vascular smooth muscle cell populated-collagen lattice contraction. J Cardiovasc Pharmacol 2004;43:808-814.
119. Singhal AB, Topcuoglu MA, Dorer DJ, Ogilvy CS, Carter BS, Koroshetz WJ: SSRI and statin use increases the risk for vaso-spasm after subarachnoid hemorrhage. Neurology 2005;64:1008-1013.
120. Parra A, Kreiter KT, Williams S, Sciacca R, Mack WJ, Naidech AM, Commichau CS, Fitzsimmons BF, Janjua N, Mayer SA, Connolly ES Jr: Effect of prior statin use on functional outcome and delayed vasospasm after acute aneurysmal subarachnoid hemorrhage: a matched controlled cohort study. Neurosurgery 2005;56:476-484.
121. McGirt MJ, Blessing R, Alexander MJ, Nim-jee SM, Woodworth GF, Friedman AH, Graffagnino C, Laskowitz DT, Lynch JR: Risk of cerebral vasopasm after subarach-noid hemorrhage reduced by st atin therapy: a multivariate analysis of an institutional experience. J Neurosurg 2006;105:671-674.
122. Tseng MY, Czosnyka M, Richards H, Pickard JD, Kirkpatrick PJ: Effects of acute treatment with pravastatin on cerebral vasospasm, autoregulation, and delayed ischemic deficits after aneurysmal subarachnoid hemorrhage: a phase II randomized placebo-controlled trial. Stroke 2005;36:1627-1632.
123. Lynch JR, Wang H, McGirt MJ, Floyd J, Friedman AH, Coon AL, Blessing R, Alexander MJ, Graffagnino C, Warner DS, Las-kowitz DT: Simvastatin reduces vasospasm after aneurysmal subarachnoid hemorrhage: results of a pilot randomized clinical trial. Stroke 2005;36:2024-2026.
124. Trimble JL, Kockler DR: Statin treatment of cerebral vasospasm after aneurysmal sub-arachnoid hemorrhage. Ann Pharmacoth-er 2007;41:2019-2023.
125. Vergouwen MD, de Haan RJ, Vermeulen M, Roos YB: Effect of statin treatment on vaso-spasm, delayed cerebral ischemia, and functional outcome in patients with aneu-rysmal subarachnoid hemorrhage: a systematic review and meta-analysis update. Stroke 2010;41:e47-e52.
126. Kambayashi J, Liu Y, Sun B, Shakur Y, Yoshitake M, Czerwiec F: Cilostazol as a unique antithrombotic agent. Curr Pharm Des 2003;9:2289-2302.
127. Katakami N, Kim YS, Kawamori R, Yama-saki Y: The phosphodiesterase inhibitor ci-lostazol induces regression of carotid atherosclerosis in subjects with type 2 diabetes mellitus: principal results of the Diabetic Atherosclerosis Prevention by Cilostazol (DA PC) study: arandomized trial. Circulation 2010;121:2584-2591.
128. Oyama N, Yagita Y, Kawamura M, Sugiya-ma Y, Terasaki Y, Omura-Matsuoka E, Sasaki T, Kitagawa K: Cilostazol, not aspirin, reduces ischemic brain injury via endothe-lial protection in spontaneously hypertensive rats. Stroke 2011;42:2571-2577.
129. Uchiyama S, Demaerschalk BM, Goto S, Shinohara Y, Gotoh F, Stone WM, Money SR, Kwon SU: Stroke prevention by cilo-stazol in patients with atherothrombosis: meta-analysis of placebo-controlled randomized trials. J Stroke Cerebrovasc Dis 2009;18:482-490.
130. Yamaguchi-Okada M, Nishizawa S, Mizu-tani A, Namba H: Multifaceted effects of selective inhibitor of phosphodiesterase III, cilostazol, for cerebral vasospasm after sub-arachnoid hemorrhage in a dog model. Cerebrovasc Dis 2009;28:135-142.
131. Nishino A, Umegaki M, Fujinaka T, Yoshi-mine T: Cilostazol attenuates cerebral vaso-spasm after experimental subarachnoid hemorrhage. Neurol Res 2010;32:873-878.
132. Ito H, Fukunaga M, Suzuki H, Miyakoda G, Ishikawa M, Yabuuchi Y, Taki W: Effect of cilostazol on delayed cerebral vasospasm after subarachnoid hemorrhage in rats: evaluation using black blood magnetic resonance imaging. Neurobiol Dis 2008;32:157-161.
133. Yoshimoto T, Shirasaka T, Fujimoto S, Yo-shidumi T, Yamauchi T, Tokuda K, Kaneko S, Kashiwaba T: Cilostazol may prevent cerebral vasospasm following subarachnoid hemorrhage. Neurol Med Chir (Tokyo) 2009;49:235-240.
134. Fujinaga K, Onoda K, Yamamoto K, Imana-ka-Yoshida K, Takao M, Shimono T, Shim-po H, Yoshida T, Yada I: Locally applied ci-lostazol suppresses neointimal hyperplasia by inhibiting tenascin-C synthesis and smooth muscle cell proliferation in free artery grafts. J Thorac Cardiovasc Surg 2004; 128:357-363.
135. Mizutani M, Okuda Y, Yamashita K: Effect of cilostazol on the production of platelet-derived growth factor in cultured human vascular endothelial cells. Biochem Mol Med 1996;57:156-158.
136. Nozaki K, Okamoto S, Uemura Y, Yanamo-to H, Kikuchi H: Changes of glycogen and ATP contents of the major cerebral arteries after experimentally produced subarach-noid haemorrhage in the dog. Acta Neuro-chir (Wien) 1990;104:38-41.
137. Suzuki H, Hasegawa Y, Chen W, Kanamaru K, Zhang JH: Recombinant osteopontin in cerebral vasospasm after subarachnoid hemorrhage. Ann Neurol 2010;68:650-660.